Sandra Shotwell

Sandra Shotwell is an experienced biotech corporate leader, board member, and consultant currently serving as the Director of Operations at TMT-Rx, a company developing treatments for fentanyl overdose.1 With a career spanning over four decades, Shotwell has established herself as a prominent figure in the biotechnology and pharmaceutical industries.

Professional Experience

Shotwell's career highlights include:

• Director of Operations at TMT-Rx (August 2023 - Present): In this role, she oversees operations for a company focused on developing treatments for fentanyl overdose.1

• Board Chair at Veana Therapeutics Inc (May 2020 - Present): Veana Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment.1

• Principal at Alta Biomedical Group (March 2000 - Present): Shotwell leads this technology commercialization consulting firm, providing services in innovation management to various clients.1

• Co-Founder, CEO, and Board Chair at ELEX BIOTECH, INC (January 2018 - December 2023): She led this drug discovery and development company focused on treatments for arrhythmia and heart failure.1

• Chief Executive Officer at DesignMedix (October 2008 - March 2020): DesignMedix targeted drug resistance in multiple diseases, with a focus on malaria treatment.1

Education

Shotwell's educational background includes:

• Post-doctoral studies in Neurobiology at Stanford University School of Medicine (1982-1984)
• Ph.D. in Biology from California Institute of Technology (1976-1982)
• AB in Physiological Psychology from Princeton University (1972-1976)1

Skills and Expertise

Sandra Shotwell is skilled in:

• Entrepreneurship
• Corporate leadership
• Deal-making
• Early-stage pharmaceutical product development
• Project management
• Biotechnology1

Her diverse experience in both academic and corporate settings has positioned her as a valuable asset in the biotech industry, particularly in the areas of drug discovery, development, and commercialization.